New CEO at Cevec Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Cevec Pharmaceuticals, a Germany biopharmaceutical company specialising in the development of therapeutic proteins using their proprietary human cell expression systems, has appointed Dr Rainer Lichtenberger chief executive officer. He succeeds Professor Stefan Kochanek, one of the founders of the company, who has led the company as interim CEO for almost half a year and will continue to serve as one of the advisory board members. Dr Lichtenberger has 20 years' management experience in companies such as the Merckle/ratiopharm group and Merck KGaA.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.